Trial Profile

A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emibetuzumab (Primary) ; Ramucirumab
Indications Adenocarcinoma; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

29 May 2019 Safety and efficacy results published in the Clinical Cancer Research.
28 Mar 2018 Status changed from active, no longer recruiting to completed.
01 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com